Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GC3114B
- Development stage
- Phase 3
- Lead developer
- GC Biopharma
- Modality
- Vaccines & Immunotherapeutics
01
Overview
GC3114B is a GC Biopharma preclinical trivalent influenza vaccine candidate intended to prevent influenza by eliciting protective immune responses against the influenza-virus components included in the vaccine. The company pipeline identifies the program as a vaccine for trivalent flu and lists it at the preclinical stage; its specific vaccine platform, strain composition, adjuvant, dosage form, and route of administration have not been publicly disclosed. (gcbiopharma.com)
02
Targets
Beyond the preview
Go deeper on GC3114B.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GC3114B.